Compare COSM & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COSM | MBAI |
|---|---|---|
| Founded | 2009 | 2004 |
| Country | United States | Israel |
| Employees | N/A | 85 |
| Industry | Other Pharmaceuticals | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5M | 12.0M |
| IPO Year | 2009 | N/A |
| Metric | COSM | MBAI |
|---|---|---|
| Price | $0.32 | $1.65 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 370.4K | 45.2K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.58 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $54,426,402.00 | N/A |
| Revenue This Year | $20.69 | N/A |
| Revenue Next Year | $53.10 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.97 | N/A |
| 52 Week Low | $0.28 | $1.31 |
| 52 Week High | $1.32 | $3.92 |
| Indicator | COSM | MBAI |
|---|---|---|
| Relative Strength Index (RSI) | 36.76 | 45.49 |
| Support Level | $0.30 | $1.44 |
| Resistance Level | $0.50 | $1.83 |
| Average True Range (ATR) | 0.03 | 0.12 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 27.07 | 29.61 |
Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.